Stamos Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.54M Sell
5,449
-680
-11% -$695K 1% 27
2026
Q1
$5.64M Buy
6,129
+1,351
+28% +$1.37M 0.88% 32
2025
Q4
$5.13M Sell
4,778
-1,424
-23% -$1.36M 0.83% 36
2025
Q3
$4.73M Buy
6,202
+818
+15% +$609K 0.89% 26
2025
Q2
$4.2M Buy
5,384
+2,639
+96% +$2.05M 0.75% 40
2025
Q1
$2.27M Buy
2,745
+805
+41% +$670K 0.59% 51
2024
Q4
$1.5M Buy
1,940
+800
+70% +$662K 0.35% 86
2024
Q3
$1.01M Buy
1,140
+550
+93% +$494K 0.24% 96
2024
Q2
$534K Sell
590
-50
-8% -$40K 0.11% 122
2024
Q1
$498K Sell
640
-230
-26% -$164K 0.11% 113
2023
Q4
$507K Buy
+870
New +$508K 0.14% 100
2023
Q1
Sell
-10,820
Closed -$3.96M 121
2022
Q4
$3.96M Sell
10,820
-5,670
-34% -$2.01M 1.25% 21
2022
Q3
$5.33M Buy
16,490
+11,750
+248% +$3.72M 1.36% 25
2022
Q2
$1.54M Buy
+4,740
New +$1.42M 0.46% 44
2019
Q2
Sell
-5,000
Closed -$644K 78
2019
Q1
$644K Hold
5,000
0.83% 36
2018
Q4
$579K Buy
+5,000
New +$559K 0.44% 53

Other funds holding LLY

Stamos Capital Partners's LLY Position: Q2 2026 in Review

Stamos Capital Partners reduced its Eli Lilly (LLY) stake by 11% in Q2 2026, selling an estimated $695K and leaving 5,449 shares worth $6.54M. The position accounts for 1% of the portfolio, ranked #27.

Stamos Capital Partners first reported a position in LLY in Q4 2018 and has held it in 16 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Stamos Capital Partners held 5,449 shares of Eli Lilly worth $6.54M as of Q2 2026.
  • Stamos Capital Partners sold 680 Eli Lilly shares in Q2 2026, an estimated $695K.
  • Eli Lilly made up 1% of Stamos Capital Partners's portfolio in Q2 2026, its #27 holding.
  • Stamos Capital Partners first reported a position in Eli Lilly in Q4 2018 and has held it in 16 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Stamos Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.